By otakuyassine3@gmail.com 
GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) CEO Katherine Stueland sold 1,657 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total value of $130,041.36. Following the completion of the transaction, the chief executive officer now directly owns 3,937 shares in the company, valued at $308,975.76. This trade represents a 29.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Katherine Stueland also recently made the following trade(s):
- On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total transaction of $4,858,161.60.
- On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total transaction of $1,407,709.08.
- On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total transaction of $805,951.75.
- On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $279,590.57.
- On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The stock was sold at an average price of $70.34, for a total value of $1,569,074.38.
- On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The stock was sold at an average price of $70.48, for a total value of $1,628,651.84.
GeneDx Price Performance
WGS stock opened at $74.85 on Monday. GeneDx Holdings Corp. has a 52 week low of $3.62 and a 52 week high of $98.87. The firm has a market capitalization of $2.06 billion, a P/E ratio of -24.07 and a beta of 2.02. The company has a fifty day simple moving average of $78.29 and a two-hundred day simple moving average of $58.33. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in WGS. Fred Alger Management LLC purchased a new stake in GeneDx during the third quarter valued at approximately $16,731,000. Zweig DiMenna Associates LLC bought a new position in shares of GeneDx during the 4th quarter valued at approximately $23,788,000. Millennium Management LLC raised its holdings in GeneDx by 193.5% during the 2nd quarter. Millennium Management LLC now owns 311,401 shares of the company’s stock valued at $8,140,000 after buying an additional 205,318 shares during the period. Raymond James & Associates bought a new stake in GeneDx in the third quarter worth $8,090,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in GeneDx during the third quarter worth $7,533,000. Institutional investors own 61.72% of the company’s stock.
Analyst Ratings Changes
WGS has been the topic of several recent analyst reports. Craig Hallum lifted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. TD Cowen lifted their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, January 7th. The Goldman Sachs Group increased their price objective on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, Wells Fargo & Company lifted their target price on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $70.67.
Check Out Our Latest Stock Report on GeneDx
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Stories
Receive News & Ratings for GeneDx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GeneDx and related companies with MarketBeat.com’s FREE daily email newsletter.